# US 8,784,776 B2 · Use of FSH receptor ligands for diagnosis and therapy of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,776 B2
- Document ID: US8784776B2
- Status: Granted
- Kind: B2
- Application number: 12/866,519
- Filed: 2009-02-18
- Published: 2010-12-16
- Granted: 2014-07-22
- Earliest claimed: 2008-02-18
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Mount Sinai School of Medicine
- Applicants: Nicolae Ghinea; Aurelian Radu
- Inventors: Nicolae Ghinea; Aurelian Radu
- Web page: https://patentgrep.com/patent/US8784776B2

## CPC

- C07K 16/2869: {against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61K 49/0002: {General or multifunctional contrast agents, e.g. chelated agents}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 51/1072: {the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate}
- A61P 35/00: Antineoplastic agents
- G01N 33/57555: of the prostate
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 2333/59: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells.

## Claims

### Claim 1

A method for imaging vessels associated with a tumor in a patient, the method comprising administering a labeled Vascular Endothelial follicle-stimulating hormone (FSH) receptor (VE-FSHR) ligand to said patient and imaging said patient to detect the in vivo binding of said ligand to a VE-FSHR in vessels associated with the tumor in said patient.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the FSH receptor (FSHR) ligand is a detectably labeled anti-FSHR antibody.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the FSH receptor (FSHR) ligand is detectably labeled FSH.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said tumor is selected from the group consisting of prostate, kidney, ovary, testis, lung, liver, pancreas, stomach, breast, colon, brain and urinary bladder cancer.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the prostate cancer is prostate adenocarcinoma.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the FSH receptor (FSHR) ligand localizes or determines the size of the tumor in vivo.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said method evaluates the severity of a cancer or monitors the efficacy of an anti-tumor therapy.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the FSH receptor (FSHR) ligand is administered intravenously.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said FSH receptor (FHSR) ligand is labeled with a gas-filled microvesicle.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said method comprises contrast enhanced ultrasound imaging.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the tumor is a primary tumor or a metastatic lesion.

### Claim 12 (depends on 1)

The method according to claim 1, wherein said vessels are blood vessels associated with the tumor.

### Claim 13 (depends on 1)

The method according to claim 1, wherein said vessels are microvessels associated with the tumor.